Search results
Showing 76 to 86 of 86 results for infliximab
Etanercept and infliximab for the treatment of psoriatic arthritis (TA104)
This guidance has been replaced by NICE technology appraisal guidance 199.
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130)
This guidance has been updated and replaced by NICE technology appraisal guidance 375.
Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.
The clinical effectiveness and cost effectiveness of infliximab for Crohn's disease (TA40)
This guidance has been updated and replaced by NICE technology appraisal guidance 187.
Discontinued Reference number: GID-TAG402
Obinutuzumab for untreated advanced follicular lymphoma (TA513)
Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.
Evidence-based recommendations on ruxolitinib (Jakavi) for treating acute graft versus host disease that has an inadequate response to corticosteroids in people 12 years and over.
Show all sections
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.
NICE recommends several treatment options to help with rheumatoid arthritis
Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today.